{
  "id": "d41a480b83527b63",
  "title": "Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER - 252 Program",
  "description": "20251210T223000Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/11/tmt-newswire/globenewswire/serina-therapeutics-submits-complete-response-to-fda-clinical-hold-letter-for-ser-252-program/2241200",
  "published_at": "20251210T223000Z",
  "fetched_at": "2025-12-11T00:23:03.006755+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/11/tmt-newswire/globenewswire/serina-therapeutics-submits-complete-response-to-fda-clinical-hold-letter-for-ser-252-program/2241200",
    "url_mobile": "https://www.manilatimes.net/2025/12/11/tmt-newswire/globenewswire/serina-therapeutics-submits-complete-response-to-fda-clinical-hold-letter-for-ser-252-program/2241200/amp",
    "title": "Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER - 252 Program",
    "seendate": "20251210T223000Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/11/862854.png",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}